Levosimendan Kalceks (Levosimendan)

Levosimendan binds to troponin C, increasing the heart muscle’s sensitivity to calcium, which enhances contractile force without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac after‑load.

The dosing regimen for Levosimendan Kalceks is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Specific infusion rates and duration are individualized and should follow local prescribing guidelines.

The safety of Levosimendan in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic‑vasodilatory profile not seen with many other agents.

Levosimendan Kalceks must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until ready for use to maintain stability and potency.

The medication is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically using a controlled infusion pump, with continuous monitoring of cardiovascular parameters throughout the infusion period.

Serious risks include severe hypotension that may require vasopressor support, life‑threatening ventricular tachyarrhythmias, and rare anaphylactic reactions. Prompt recognition and management of these events are essential during and after infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals receiving strong CYP3A4 inhibitors that could markedly increase drug exposure. Clinical judgment should guide use in patients with significant hepatic impairment.